IL6 and breast cancer: The increase in IL-6 in animals pretreated with P2Et could, in fact, be a consequence of the pre-activation of the immune system and not a direct effect of P2Et, since we observed that IL-6 decreased in response to treatment with P2Et in the present work and in the 4T1 breast cancer model in a previous study (18).